🇺🇸

US SEC Filing Intelligence

· daily

US IPO Pipeline SEC S-1 Filings — April 15, 2026

The IPO pipeline shows robust activity with 4 S-1 filings for new offerings (2 SPACs at $75M and $100M, 1 health tech IPO, 1 post-SPAC resale), alongside resale registrations highlighting dilution risks and 3 merger-related S-4s, signaling continued SPAC and M&A momentum into 2026. Limited explicit period-over-period data across filings, but Barfresh demonstrates operational expansion with 18% supply increase in Q4 2025 post-Arps Dairy acquisition (Oct 3, 2025) vs prior reliance on third parties, while Soluna's SEPA utilization shows 3M shares issued since Aug 2024 (now 113M outstanding). Neutral sentiment dominates (7/9 filings), with mixed tones on PRC risks and historical losses; no YoY revenue/margin trends detailed, but capital raises (e.g., Barfresh $7.5M in Mar 2026 to retire $2.5M debt) indicate deleveraging. Critical developments include FortuneX and AI Strategy SPAC IPOs targeting high-growth PRC/AI themes amid regulatory risks, and ROKIT's Nasdaq debut in NMN supplements/AI regen. Portfolio-level patterns reveal SPAC dominance (4/9), resale dilution potential averaging ~20-30% share increase (Soluna/Barfresh/Merlin), and forward catalysts like Barfresh's 44k sq ft facility online late 2026. Market implications: Opportunity in new listings but caution on dilutions and combo timelines (15-24 months for SPACs).

9 high priority 9 total filings
· daily

Global High-Priority Regulatory Events — April 15, 2026

Across 50 filings in the Global High Priority Market Events stream, dominant themes include financial distress with 3 insolvencies/delays (Radhagobind, Gala Global, Stanpacks context), high promoter encumbrances/pledges (Camlin Fine Sciences at 96.32% of holdings), and active M&A/takeover activity (Simandhar open offer at Rs301/share, Galera-Obsidian merger, Leidos JV, Spire $650M asset sale). Period-over-period trends show mixed revenue performance: 12/20 annual reports (10-K/20-F) with growth (e.g., Futu +68.1% YoY, Chunghwa +2.7% YoY, Veea +57% YoY) but 8 with sharp declines (Eightco -16.76% YoY, Polar Power -55% YoY, Autohome -8.3% YoY); margins compressed in 6 firms (avg -100bps, e.g., Ceragon 33.8% vs 34.7%). Positive catalysts include leadership appointments (Structure Therapeutics COO, World Acceptance interim CEO) and capital raises, while regulatory penalties and Nasdaq delisting risks (Soluna) signal caution. Portfolio-level, Indian firms show promoter shifts/insolvency risks (5/10), US biotechs M&A bullish (Galera, Aspire LOI), China/Taiwan ADRs mixed growth with dividend stability. Implications: Avoid distress names short-term, target M&A plays for upside, monitor Q2-Q3 2026 closings for catalysts.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 15, 2026

Across 50 US SEC 10-K filings for FY2025 (period ending ~Dec 31, 2025), small-cap and micro-cap companies dominate with mixed sentiment (28/50 mixed, 10 negative), reflecting persistent operating losses amid revenue volatility: 22 companies saw revenue declines (avg -35% YoY, e.g., Polar Power -55%, Cenntro -42%), while 12 posted growth (avg +85% YoY, outliers Gloo Holdings +308%, Vivakor segment +87%). Net losses widened in 60% of filers (avg +50% YoY magnitude), driven by R&D/SG&A spikes and impairments, though 8 achieved profitability swings via one-offs (e.g., Oncotelic +$249M from investment fair value). Balance sheets improved via $1B+ aggregate financing (equity/debt), boosting cash/assets in 65% but deepening dilutions/shareholder deficits elsewhere; cash burn worsened in 70% (avg +40% YoY operating use). SPACs (e.g., Horizon Space, Constellation) faced heavy redemptions (avg 90% trust erosion), signaling de-SPAC fatigue. Biotech/pharma (12/50) showed R&D escalation (+100% avg) with commercialization catalysts, while energy/mining had modest production gains. Implications: Favor turnaround outliers with revenue ramps and monitor liquidity risks; portfolio tilt to revenue growers like Citi Trends amid broad weakness.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — April 15, 2026

Three small-cap companies—Soluna Holdings (SLNH), Alaunos Therapeutics, and BioCardia (BCDA)—disclosed Nasdaq non-compliance notices between April 9-10, 2026, highlighting acute financial distress with negative sentiment across all filings (materiality 9/10). Soluna faces bid price deficiency below $1.00 for 30 consecutive days under Rule 5550(a)(2), while Alaunos and BioCardia report critically low stockholders' equity ($2.153M and $895K respectively vs. $2.5M minimum under Rule 5550(b)(1)), with BioCardia's level representing only 36% of requirement (worst outlier). No enriched period-over-period trends (YoY/QoQ revenue, margins) or insider activity provided, implying persistent deterioration without management support via buys. Forward-looking compliance deadlines offer narrow paths to avoidance: SLNH has 180 days to October 7, 2026, for price cure; others must submit plans by May 25-26, 2026, for potential 180-day extensions. Common portfolio-level pattern: small-cap vulnerability to Nasdaq standards, bearish for share prices with delisting risks amplifying volatility. No capital allocation (dividends/buybacks) or M&A activity noted, underscoring cash constraints. Trading continues unaffected now, but failures could trigger OTC delistings and sharp declines.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 15, 2026

Across 39 filings in the USA Corporate Distress & Bankruptcy stream, key themes include Nasdaq listing compliance crises in 4 small-cap biotechs/techs (Soluna, Alaunos, BioCardia, Mainz with equity deficits from $641k-$2.15M vs $2.5M min), high debt/concentration risks (Strawberry Fields REIT $752M debt, 86.8% rent from 15 leases), and deleveraging actions via asset sales (Spire $650M, Owens Corning $645M EV post-impairment), debt settlements (Visium $182k, SUNation $1.2M conversion), and equity raises (Graham $50M, Traws $10M PIPE). Credit facility amendments/extensions (Flowserve $1.45B, Federal Realty $1.4B, Leidos/U.S. Physical Therapy) signal proactive liquidity management amid potential distress, with no broad YoY revenue/margin declines but equity erosion in biotechs. Positive M&A/JVs (Tilray Lyphe accretive 2027, Limoneira composting FY2027) offer turnaround plays. Portfolio-level: 12/39 show debt reduction/capital inflows vs 7 Nasdaq risks; implications: short Nasdaq non-compliant, long deleveraging industrials/utilities.

39 high priority 39 total filings
· daily

US Executive Officer Management Changes SEC — April 15, 2026

Across 29 filings on US executive and director changes from April 2026, the dominant theme is leadership transitions with 14 appointments/promotions (48%), 11 resignations/departures (38%), 3 compensation enhancements, and 1 CEO return from medical leave, signaling a mix of proactive team-building in biotech/energy and reactive stability measures amid M&A. Positive sentiment prevails in 8 filings (28%), particularly biotechs (Structure Therapeutics, Prelude, Tango) hiring for Phase 3/clinical catalysts and media (Cineverse, Regis) for growth strategies, while 17 neutrals (59%) reflect routine no-disagreement exits; no explicit YoY revenue/margin declines but comp increases (e.g., Hallador CEO +18.5% YoY base) indicate retention amid $68M EBITDA targets. Portfolio-level patterns show healthcare/biotech outliers with experienced hires boosting pipelines (e.g., 30+ years oncology exp at Prelude), contrasting finance/industrials' interim roles (Corebridge, Kenvue pre-merger). Critical implications include M&A risks (Corebridge $385B AUM merger), board contractions (DuPont 11→10, American Vanguard 9→7 per debt terms), and 2026 catalysts like clinical data (Tango vopimetostat). No broad insider trading patterns but shareholder designees (Hagerty, Ribbon) suggest alignment; capital allocation leans retention via RSUs/sev (Lionsgate 4.5M options, Hallador $2.4M CIC). Actionable: Favor biotech hires for alpha, monitor interims for volatility.

29 high priority 29 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 15, 2026

Across 29 US SEC filings on boardroom changes (Apr 15, 2026 period), leadership churn dominates with 14 resignations/departures (e.g., CEOs at World Acceptance/Trans-Lux, CFOs at LENSAR/Corebridge/Kenvue, directors at Figma/OGE/ESS/DuPont/American Vanguard/Hagerty/USBC) and 13 appointments/promotions (strong in biotech: Structure/Prelude/Tango/Cineverse adding pipeline/ops expertise). Sentiment skews neutral (19/29) but positive in biotech/media (9/29) signaling strategic bolstering for trials/acquisitions; no uniform YoY/QoQ financial trends but comp hikes (Hallador CEO +18.5% to $800k, $68M Adj EBITDA target) and equity grants (Lionsgate $10M annual) reflect confidence. Insider-linked activity minimal but shareholder designees (Hagerty/Ribbon) and major holder reps (Regis) indicate alignment. Forward catalysts cluster Q2 2026 (clinical data, Phase 3 trials, mergers); portfolio trend: Biotech leadership upgrades for 2026 catalysts vs small-cap turnover risks. Implications: Favor biotech hires for alpha, monitor interims amid M&A (Corebridge/Kenvue), neutral on routine director exits.

29 high priority 29 total filings
· daily

US Merger & Acquisition SEC Filings — April 15, 2026

Across 9 SPAC filings in USA M&A & Takeover Activity, a dominant theme is deadline extensions and amendments in 6/9 cases (Pantages, Keen Vision, Ribbon, SIM, WinVest, indirectly Spring Valley), signaling sponsor commitment amid no completed deals, with total extension funding ~$335k via trust deposits and notes. Positive outliers include board expertise addition at Launchpad Cadenza and strategic tailings acquisition for Plum III's rare earth project (1.5M tons for 3M shares), contrasting mixed risks in Spring Valley's fusion merger. No YoY/QoQ operating trends available as pre-merger entities, but capital allocation trends show increasing sponsor loans/deposits (e.g., Ribbon $125k, WinVest $180k note with $60k drawn). Neutral-to-positive sentiment prevails (2 positive, 6 neutral, 1 mixed), with materiality highest (8/10) for active M&A updates. Portfolio-level pattern: SPAC sector under deadline pressure (original deadlines April-May 2026), driving activity spikes; implications include short-term upside on catalyst hits but redemption risks if unfulfilled. Forward-looking catalysts cluster late April, positioning for de-SPAC announcements.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 15, 2026

Overnight SEC filings reveal mixed financial performances across sectors, with banks like M&T showing 14% YoY net income growth but 13% QoQ declines, telecoms like Chunghwa Telecom up 2.7% YoY revenues amid flat margins, and sharp contrasts in small caps (Veea losses narrowed 86% YoY vs Eightco's $262M net loss on 17% revenue drop). Biotech and SPAC activity surges with mergers (Galera-Obsidian all-stock deal, Pasqal quantum SPAC with $400M funding, FG Merger-BOXABL at $3.5B valuation), while restructuring dominates (Snap 16% headcount cut for $500M savings) and dilution risks loom in low-float names (Soluna Nasdaq warning, Lunai reverse split). Capital raises are bullish (TeraWulf $900M offering, Brookfield $1B notes), but portfolio-level trends show 5/15 high-materiality firms with YoY revenue declines averaging -15% (outliers: Sonim 0%, Tradewinds -22%). M&A tax clarifications (Mission Produce cap $5M) reduce risks, yet going concern doubts persist in 3 biotechs/dev firms. Institutional 13Fs (12 filings) indicate ETF-heavy portfolios (e.g., S&P 500, QQQ dominance) signaling broad market stability. Actionable: Favor energy/crypto raises and biotech catalysts over distressed small caps ahead of market open.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 14, 2026

Across 14 filings in the USA S&P 500 Technology stream, overarching themes include steady institutional portfolios (5/14 are 13Fs with no reported changes, heavy ETF and select tech exposure like Intel at $5.7B in Murphy Pohlad), governance shifts (board refreshes at ImmuCell, bylaw amendments at GameSquare, reverse split at Immunic), and mixed financials in non-core holdings (revenue declines at Saga Communications -5.1% YoY, loss narrowing at Bravo -41% expense cut). Period-over-period trends show deterioration in select areas: Saga's net operating revenue down 5.1% YoY to $107M with full goodwill impairment to $0, Bravo cash down 61% YoY to $111 amid 32% liability rise, but station expenses flat -0.1% at Saga. Critical developments include AParadise SPAC merger progress with Enhanced Ltd at $1.2B EV and May 1 meeting, ImmuCell's positive board bolstering animal health innovation, and Immunic's 1-for-10 reverse split effective April 27. Portfolio-level patterns reveal institutional conviction in tech outliers like Intel ($5.7B top holding) and Cisco ($1.5M), contrasting bearish signals from impairments and cash drains, signaling selective opportunities amid governance catalysts in May-June 2026.

6 high priority 8 medium 14 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 14, 2026

Across 17 SEC filings from NASDAQ-100 stream companies and related entities on April 14, 2026, dominant themes include corporate governance shifts (Meta directors departing, ImmuCell board refresh with new Strategy Committee), high-profile M&A (Amazon's acquisition of Globalstar, AParadise SPAC merger with Enhanced at $1.2B EV), and mixed annual results (Saga revenue -5.1% YoY to $107M with $20M+ impairments driving net loss -$1.22 EPS vs +$0.55 prior; Bravo net loss improved 36% YoY to -$253K via 41% expense cuts but cash -61% to $111). Institutional 13F-HRs reveal stable, diversified ETF-heavy portfolios (e.g., Murphy Pohlad $279B AUM with Intel/Chevron tops, no changes noted). Period-over-period trends show media weakness (Saga flat expenses but market share dips in Milwaukee/Columbus) contrasting small-cap cost discipline (Bravo G&A -77% YoY); no broad insider trading signals but board changes signal potential strategy pivots. Forward catalysts cluster in May-June (SPAC votes, reverse splits, AGMs), with Amazon M&A implying telecom expansion amid neutral-to-positive sentiments (9/17 positive/mixed). Portfolio implications: Watch tech M&A for upside, media impairments for downside risks, governance for conviction gauges.

9 high priority 8 medium 17 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 14, 2026

Across 50 diverse SEC filings labeled under USA S&P 500 Financials (though spanning energy, healthcare, biotech, and industrials), key themes include a surge in M&A/takeover activity with attractive premiums (e.g., Avanos +72%, Day One $21.50/share), mixed Q1/FY results showing YoY revenue gains in banks like Wells Fargo (+6%) and Unity Bancorp (+12.8% NII) but QoQ softness and rising provisions, and neutral 13F holdings with no major shifts. Period-over-period trends reveal 6/12 earnings filings with YoY net income growth (avg +10%) offset by margin compression in 5/10 (avg -150bps, e.g., AstroNova -7.4% gross profit), while capital allocation favors dividends/buybacks (Unity +7%, Wells $4B repurchase). Forward-looking catalysts cluster in H2 2026 M&A closings and energy transition deals (DevvStream/XCF targeting $1B revenue). Portfolio-level, financials show loan/deposit growth (Unity +10.9%/+YoY) but credit provisions spiking (Wells +1095% YoY), signaling caution amid stable charge-offs. Implications: Tactical M&A arbitrage opportunities, monitor bank NIM/provisions, flat institutional conviction per 13Fs.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 14, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader financial and operational crossovers), dominant themes include strong YoY revenue and net income growth in major financial institutions like JPMorgan (+13% NI, +10% revenue), BlackRock (+27% revenue, $130B inflows), and Wells Fargo (+7% NI, +15% EPS), offset by rising credit provisions (Wells +1093% YoY) and mixed segment results. Consumer Staples highlights feature stable capital returns from Procter & Gamble (quarterly dividend $1.0885, record date Apr 24) and Hershey (exec departure neutral), alongside Celsius Holdings' steady 8.6-8.97% insider ownership amid proxy battles. Small-cap operators show sharp declines, e.g., Greystone Logistics sales -45% YoY 9M to $22M, Nature's Miracle revenue -97.6% YoY Q3, and Chipmos net profit -61.7% YoY amid margin compression to 10.8%. Portfolio-level trends reveal 4/7 key financial reporters with +6-27% YoY revenue growth but 3/5 with margin/operating pressures; capital allocation favors dividends (P&G, BlackRock +10%) and buybacks (Wells $4B, BlackRock $450M). Board/governance changes prevalent in 12/50 filings (e.g., appointments at ImmuCell, Invesco Mortgage), signaling strategic shifts. Actionable implications: Favor large-cap financials with consumer exposure for growth, monitor staples leadership stability and small-cap restatements for downside risks.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 14, 2026

Across 50 filings in the USA S&P 500 Industrials stream, 13F-HR reports dominate (e.g., Regent Peak, Runnymede, multiple American State Bank filings), revealing a portfolio-level pattern of heavy concentration in non-industrial mega-caps like Nvidia (top holding in 10+ filers, values up to $21.5M), Apple, and Microsoft, signaling institutional conviction in tech proxies amid industrial sector caution. Company-specific filings show mixed period-over-period trends: revenue growth in select areas (Heritage Distilling +20.4% YoY total net revenues, Unity Bancorp loans +10.9% YoY) contrasted by declines (Saga Communications -5.1% YoY revenue, Alphega net loss +92% YoY) and cash flow volatility (Antalpha financing cash -86% YoY). M&A activity surges in industrials-adjacent spaces like robotics (Serve Robotics acquisition complete, AgEagle $10M JV in counter-drones) and renewables (XCF Global/DevvStream/Southern merger targeting $1B revenue), with positive sentiment. Capital allocation mixed: dividend hikes (Unity +7% to $0.16, Ohio Valley $0.25) vs cuts (Saga -37.5% to $1.00). Forward-looking catalysts cluster in Q2 2026 AGMs (REGENXBIO May 29, Northrim May 28, ImmuCell June 11) and merger milestones (XCF $400M bonds, $1B revenue by Jun 30). Overall neutral-mixed sentiment (20+ neutral 13Fs), with actionable alpha in M&A execution risks and tech-tilted industrials exposure.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 14, 2026

Across the USA S&P 500 Energy intelligence stream, six filings highlight mixed sentiment dominated by operational volatility in APA Corp's preliminary 1Q26 results, showing robust international oil prices at $85.70/bbl and a $244M pre-tax net gain on purchases/sales, contrasted by negative US natural gas prices at $(0.35)/Mcf triggering 88 MMcf/d gas and 6,800 bbl/d NGL curtailments. OKMIN Resources reports a merger termination setback but secures $54k via dilutive private placement, while SunCoke Energy issues minor proxy corrections ahead of its May 14 AGM. Non-core filings include Silchester International's stable 13F-HR with $115.6B portfolio heavily tilted to non-energy names like Nutrien ($98.8B position), and AParadise Acquisition Corp's advancing $1.2B SPAC merger with Enhanced Ltd toward a May 1 vote and NYSE listing as ENHA. Limited period-over-period data reveals no broad YoY/QoQ trends across the group, but APA's elevated $115M G&A (incl. $25M higher stock-based comp) and $66M commodity derivative losses signal cost pressures amid price swings. Portfolio-level patterns point to May catalyst clustering (earnings, AGMs, votes) and M&A turbulence, with implications for near-term volatility in energy production and services amid US gas weakness versus international oil resilience.

3 high priority 3 medium 6 total filings
· daily

US Material Events SEC 8-K Filings — April 14, 2026

Across 50 8-K filings from April 14, 2026, dominant themes include a surge in M&A activity (8 deals: take-privates, mergers, JVs valued at >$2B total), extensive board/officer changes (25+ resignations/appointments, mostly neutral/positive for strategic alignment), and mixed financing events ($1.5B+ raised via equity/debt/credit but 4 distress signals). Period-over-period trends where disclosed show resilience (Assertio continuing ops revenue +9.7% YoY to $68.2M despite wider $31.3M net loss; no declines in 40/50 filings) but outliers like SunPower (GAAP revenue $300M down with margins -600bps to 43%) and Hydrofarm (interest default Jan 2026). Critical developments: Avanos 72% premium takeover ($1.27B EV), Lucid $750M funding+CEO shift, Horizon-Monroe BDC merger ($471M pro forma NA); bearish Hydrofarm forbearance, CERO dilutive note. Portfolio-level: Energy transition (6 filings) bullish on $1B+ rev targets; healthcare M&A active; BDCs consolidating. Implications: Arbitrage opps in deals, watch liquidity in small caps, positive capital alloc (Dow 459th div, CareCloud $3.2M savings).

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 14, 2026

Across 50 filings dated April 14, 2026, for the USA Dow Jones 30 stream, institutional 13F-HR reports (25+ filings) reveal overwhelming conviction in mega-cap tech with NVDA, AAPL, MSFT, and AMZN comprising top holdings in $100B+ portfolios, signaling sustained bullish bias amid no reported changes QoQ. Blue-chip earners show resilience: JNJ Q1 sales +9.9% YoY (raised FY2026 guidance to $100.8B, +7%), JPM net income +13% YoY ($16.5B), but mixed EPS/FCF trends (JNJ GAAP NI -52%). Healthcare catalysts dominate with Travere's first-ever FSGS FDA approval (46% proteinuria cut) and Avanos $1.27B buyout at 72% premium; energy M&A surges via XCF/DevvStream/Southern merger targeting $1B rev by Jun 30. Small caps flash distress: Hydrofarm loan forbearance post-default, Alphega loss +92% YoY, American Battery ICFR weaknesses. Capital allocation favors dividends (Unity +7%, Dow 459th consecutive $0.35, Ohio Valley $0.25). Portfolio trends: Revenue +10-20% YoY avg in reporters, but margins mixed (-7% gross AstroNova); DJ30-exposed names (JNJ, JPM, DOW) outperform small caps, implying buy blue-chips, avoid distressed.

17 high priority 33 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 14, 2026

Across 50 SEC filings for April 14, 2026, dominant themes include a surge in M&A activity particularly in biotech/healthcare (Avanos, Day One, Kezar) and energy transition (DevvStream/XCF/Southern mergers), mixed bank earnings with YoY growth but QoQ softness (Unity Bancorp +23% YoY NI, Wells Fargo +7% YoY), and revenue declines in small caps/industrials (Northann -11% YoY, SemiLEDs -90% YoY Q revenue). Period-over-period trends show 6/15 earnings filings with YoY revenue growth averaging +9% but QoQ mixed (-2% avg), margin compressions in 5/10 (avg -100bps), and positive capital returns like Unity's 7% dividend hike and Wells Fargo's $4B buyback. Neutral 13F filings (9 total) reveal persistent tech concentration (NVDA top in 4 portfolios). Critical developments: Travere's FDA approval for FILSPARI (46% proteinuria reduction), Westlake's $67M antitrust settlement, and Hydrofarm's debt forbearance signal sector risks. Portfolio-level: Healthcare M&A premiums average 70%+, energy backlog builds through 2030, but microcaps face restatements/declines; actionable now on catalysts like H2 2026 deal closes.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 14, 2026

Across 50 SEC filings from April 14, 2026, primarily non-Consumer Discretionary but including financials, energy, tech, and SPACs, key themes emerge in M&A activity (7 deals with positive/mixed sentiment), stable institutional 13F holdings heavily tilted to ETFs/tech (9 filings showing no changes), and mixed financial performance with revenue growth in 5/12 reporting companies (avg +27% YoY) offset by widening losses in development-stage firms. Period-over-period trends show YoY revenue gains (e.g., Full Truck Alliance +11.1%, Digital Brand Media +40.1% Q1) but margin pressures and rising provisions (Wells Fargo provisions +1094% YoY to $11.1B); capital allocation leans positive with dividend hikes (FNB +8%) and buybacks ($250M new program). Critical developments include merger closures (Horizon Technology positive) and distress signals (Hydrofarm forbearance, Gulf Resources 10-K delay), implying opportunities in consolidations but risks in liquidity-constrained names. Portfolio-level patterns: 6/10 financial filings bullish on returns to shareholders, contrasting negative debt events in 3 energy/industrials; no S&P 500 Consumer Discretionary pure-plays but cross-sector insights flag M&A as a growth driver amid stable institutional conviction.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 14, 2026

Across 50 filings in the USA S&P 500 Healthcare stream, healthcare-specific insights reveal mixed Q1 2026 performance with Johnson & Johnson posting 9.9% YoY sales growth but 52.4% GAAP EPS decline, offset by raised FY2026 guidance (sales +7.0%, EPS +7.1%); biotech sector shows M&A momentum (Kezar tender at $6.955/share + CVR) and catalysts (Praxis NDA accepted, PDUFA Jan 29 2027). Aggregate trends indicate revenue acceleration in pharma (JNJ +9.9%, BeOne +40.2% YoY to $5.343B) but widening losses in pre-clinical biotechs (Accustem net loss +16.7% to $1.756M). Non-healthcare filings dominate (31/50 are 13F-HR neutral snapshots heavy in ETFs/tech like Apple/MSFT/NVDA, no changes), signaling advisor caution or stability; capital raises proliferate (Lucid $550M, Cingulate resale registration). Portfolio-level: 5/10 key healthcare firms raised/reiterated guidance, but 4/10 reported margin dips or expense surges (e.g., New Horizon R&D +867% YoY). Critical implications: Biotech alpha from catalysts/M&A, but dilution risks in small caps; watch advisor 13Fs for healthcare rotations.

12 high priority 38 medium 50 total filings